Levin Warns Biotech Institutions Are Fracturing
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Jeremy Levin, founder and chairman of Ovid Therapeutics and former CEO of Teva Pharmaceuticals, argues that regulators, investors, and public trust in science are all beginning to fracture despite accelerating scientific breakthroughs
- Levin lays out his case in a new book, "Biotech in the Balance: Saving a Strategic Industry in an Age of Distrust," citing political upheaval, weakening institutions, short-term investing, and eroding public trust as the core threats
- Levin is pushing for federal policy changes designed to incentivize biotech investment, framing the issue as one of US strategic competitiveness
- Levin called on pharmaceutical companies to publicly call out how regulatory upheaval is harming the drug industry, saying "the titans are dead silent right now"
- The interview aired on STAT's "The Readout Loud" podcast with hosts Elaine Chen, Adam Feuerstein, and Allison DeAngelis
Why it matters: Levin — a former Teva CEO with industry credibility — is publicly pressuring the largest pharmaceutical companies to break their silence on regulatory disruption, arguing that the science is surging but the institutional scaffolding is crumbling. If the industry's most senior voices remain quiet, federal policymakers may face less organized pushback against regulatory changes that could shape drug development and investment for years.
Ask SkimNews
